You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 299 No. 9, March 5, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Psychiatry
 •Statistics and Research Methods
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Loss of Serendipity in Psychopharmacology

Donald F. Klein, MD, DSc

JAMA. 2008;299(9):1063-1065.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

This Commentary on the psychopharmacological revolution focuses on 2 mysteries: fostering medication discovery and finding out how they work. When I entered psychiatric training in 1953 at Creedmoor State Hospital, a 6000-bed institution with few therapeutic aspirations, psychotropic drugs were an impossible dream. For those individuals who have not had such an experience, an extremely morbid imagination is needed to conjure up that bedlam. It was rendered just tolerable by knowing that this training made one fit to be a candidate psychoanalyst. The next 2 years were spent at the US Public Health Service Hospital in Lexington, Kentucky, a 1000-bed federal therapeutic prison for opioid addicts, which amazingly included the most advanced center for human psychopharmacological experimentation in the world. The Addiction Research Center, led by the rigorous scientists Wikler and Isbell,1 incisively demanded objective, unbiased work and conducted pioneering studies of chlorpromazine, reserpine, and . . . [Full Text of this Article]

Author Affiliations: Phyllis Green and Randolph Cowen Institute for Pediatric Neuroscience, NYU Child Study Center, NYU Medical Center; Nathan S. Kline Institute for Psychiatric Research; and Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Challenges in the Search for Drugs to Treat Central Nervous System Disorders
Enna and Williams
J. Pharmacol. Exp. Ther. 2009;329:404-411.
ABSTRACT | FULL TEXT  

The Dawn of Anxiolytics: Frank M. Berger, 1913-2008
Balon
Am. J. Psychiatry 2008;165:1531-1531.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.